126 related articles for article (PubMed ID: 34180367)
21. Developing μSpherePlatform Using a Commercial Hairbrush: An Agarose 3D Culture Platform for Deep-Tissue Imaging of Prostate Cancer.
Krishnan MA; Chelvam V
ACS Appl Bio Mater; 2021 May; 4(5):4254-4270. PubMed ID: 35006838
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).
Shen D; Xie F; Edwards WB
PLoS One; 2013; 8(7):e68339. PubMed ID: 23935860
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Ha H; Kwon H; Lim T; Jang J; Park SK; Byun Y
Expert Opin Ther Pat; 2021 Jun; 31(6):525-547. PubMed ID: 33459068
[TBL] [Abstract][Full Text] [Related]
24. Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.
Derks YHW; van Lith SAM; Amatdjais-Groenen HIV; Wouters LWM; Kip A; Franssen GM; Laverman P; Löwik DWPM; Heskamp S; Rijpkema M
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2425-2435. PubMed ID: 35029739
[TBL] [Abstract][Full Text] [Related]
25. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
[TBL] [Abstract][Full Text] [Related]
26. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
27. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.
Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W
Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903
[TBL] [Abstract][Full Text] [Related]
28. Optimization of ODAP-Urea-based dual-modality PSMA targeting probes for sequential PET-CT and optical imaging.
Li Y; Duan X; Xu H; Zhang J; Zhou H; Zhang X; Zhang J; Yang Z; Hu Z; Zhang N; Tian J; Yang X
Bioorg Med Chem; 2022 Jul; 66():116810. PubMed ID: 35580538
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
30. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and evaluation of a novel urea-based
Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
Kularatne SA; Wang K; Santhapuram HK; Low PS
Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic accuracy of
Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
[TBL] [Abstract][Full Text] [Related]
35. Development of targeted near-infrared imaging agents for prostate cancer.
Wang X; Huang SS; Heston WD; Guo H; Wang BC; Basilion JP
Mol Cancer Ther; 2014 Nov; 13(11):2595-606. PubMed ID: 25239933
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.
Chen Y; Pullambhatla M; Banerjee SR; Byun Y; Stathis M; Rojas C; Slusher BS; Mease RC; Pomper MG
Bioconjug Chem; 2012 Dec; 23(12):2377-85. PubMed ID: 23157641
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
38. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
Kawada T; Yanagisawa T; Rajwa P; Sari Motlagh R; Mostafaei H; Quhal F; Laukhtina E; Aydh A; König F; Pallauf M; Pradere B; Ceci F; Baltzer PAT; Hacker M; Rasul S; Karakiewicz PI; Araki M; Nasu Y; Shariat SF
Eur Urol Oncol; 2022 Aug; 5(4):390-400. PubMed ID: 35715320
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for
Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW
Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]